NOTRELOAD AI
  • NOTRELOAD AI
  • myNOTRELOAD
  • One-Time License
  • Invest ↗
  • XY Feed
  • Push Notifications
Sign in Subscribe

FDA Clears Fate Therapeutics’ Dual-Target CAR-T FT839 for Autoimmune Diseases

Following positive FT819 data in systemic sclerosis, the company now targets multiple autoimmune indications.

FDA Clears Fate Therapeutics’ Dual-Target CAR-T FT839 for Autoimmune Diseases
Credit: Fate Therapeutics
Already have an account? Sign in.
07/09/2026 · 1:08 PM
FATE
/ Don’t stop at just one post.

Related↓

10/31/2025 · 9:15 AM

Biotech Upgrades: FATE, IMCR, IMRX Get Bullish Analyst Calls

Analysts upgrade Fate Therapeutics to Buy and initiate bullish coverage on Immunocore and Immuneering, citing promising drug trials and strong revenue potential in lupus and cancer treatments.

/ Subscriber only
/ Read more

Feed↓

Abivax Stock Drops After Short-Seller Calls Its Main Drug Toxic
Featured/ 11/20/2026 · 5:27 PM

Abivax Stock Drops After Short-Seller Calls Its Main Drug Toxic

Abivax shares fell after Scorpion Capital claimed its ulcerative colitis drug is toxic. The company rejected the report and reaffirmed its Phase 3 data.

/ Subscriber only
CrowdStrike Explores Acquisition of Zscaler in Major Cybersecurity Consolidation
Featured/ 11/20/2026 · 4:55 PM

CrowdStrike Explores Acquisition of Zscaler in Major Cybersecurity Consolidation

CrowdStrike is reportedly in talks to acquire Zscaler in a potential $265 billion cybersecurity deal, one of the largest in the sector.

/ Subscriber only
Canadian Solar Stock Tumbles on Report of Advisors Exploring Asset Sales and Bankruptcy
11/20/2026 · 3:40 PM

Canadian Solar Stock Tumbles on Report of Advisors Exploring Asset Sales and Bankruptcy

Canadian Solar shares fell sharply after a report that the solar firm and its Recurrent Energy unit are considering asset sales and a possible Chapter 11 filing.

/ Subscriber only
Explore
  • NOTRELOAD AI
  • myNOTRELOAD
  • One-Time License
  • Invest ↗
  • XY Feed
  • Push Notifications
More
  • Sign up
  • Sign in
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Terms/Privacy
  • UP↑
Get alerts

Be the first to know when deals break, stocks move, or biotech headlines hit.

Email address Subscribe
DON'T FALL BEHIND. ©2026
For informational purposes only. Not financial advice.
NOTRELOAD AI